An interview with Dr. Louis B. Chaykin of Meridien Research, about a discovery in the world of diabetes.

Here’s an interview with Dr. Louis Chaykin, as he discuss a critical discovery in the world of diabetes research.

Click here link to watch the interview on WWSB, or read the full article below.

Since 2008 the FDA has required all new diabetes drugs to undergo rigorous trials to demonstrate no increased risk of heart attack, stroke or death.

But, now there is good news for people with type-2 diabetes.

U.S regulators are now allowing the drug maker, Eli Lilly and Co. to state that its’ diabetes drug Jardiance reduces risk of death from heart problems.

 Researcher and diabetes doctor Louis Chakin, M.D.,  OF Meridien Research in Lakewood Ranch was involved with EMPA-REG cardiovascular outcome trial  from 2011 to 2015.

Dr. Chaykin shared the results revealed at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden in 2015.

“It was the first drug that has ever been approved for diabetes that has demonstrated a dramatic reduction in people dying from cardiovascular disease and total death from diabetes. The 3,000 attendees all stood up and applauded because this was such a surprise,” said Dr. Chaykin.

The study had unexpectedly found Jardiance slashed deaths dramatically in patients with type-2 Diabetes, at risk of heart attack and stroke, when added to standard diabetes medications.

 “Jardiance demonstrated a 32% to 38% reduction of people dying from cardiovascular disease or total death,” explained Dr. Chaykin. “The most interesting part is that this improvement occurred within three months of taking the drug.”

Dr Chaykin added that the hope is that Jardience will also help prevent cardiovascular disease, and early death from it for people that are newly diagnosed with type-2 diabetes.

Diabetes is the 7th leading cause of death in the United States. Dr. Louis Chaykin has treated a wide range of patients with diabetes and authored many studies on the latest therapeutic medications. He has also worked very closely with the American Diabetes Association through research, promoting awareness, and fundraising. For more information on Meridien Research or the work we do with diabetes, please contact us at 888-777-8839.